KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Arbutus Biopharma (ABUS) over the last 16 years, with Q3 2025 value amounting to $4.7 million.

  • Arbutus Biopharma's Accounts Payables fell 3832.18% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year decrease of 3832.18%. This contributed to the annual value of $7.6 million for FY2024, which is 2635.58% down from last year.
  • Arbutus Biopharma's Accounts Payables amounted to $4.7 million in Q3 2025, which was down 3832.18% from $4.5 million recorded in Q2 2025.
  • Arbutus Biopharma's Accounts Payables' 5-year high stood at $16.0 million during Q4 2022, with a 5-year trough of $4.5 million in Q2 2025.
  • For the 5-year period, Arbutus Biopharma's Accounts Payables averaged around $9.4 million, with its median value being $9.7 million (2023).
  • Its Accounts Payables has fluctuated over the past 5 years, first soared by 7007.01% in 2021, then crashed by 5941.66% in 2025.
  • Arbutus Biopharma's Accounts Payables (Quarter) stood at $10.8 million in 2021, then surged by 47.9% to $16.0 million in 2022, then tumbled by 35.92% to $10.3 million in 2023, then dropped by 26.36% to $7.6 million in 2024, then plummeted by 38.48% to $4.7 million in 2025.
  • Its Accounts Payables stands at $4.7 million for Q3 2025, versus $4.5 million for Q2 2025 and $12.1 million for Q1 2025.